Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance

Zoernig,Inka; Ziegelmeier,Claudia; Lahrmann,Bernd; Grabe,Niels; Jäger,Dirk; Halama,Niels

doi:10.3892/or.2013.2324

Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance

Authors:
- Inka Zoernig
- Claudia Ziegelmeier
- Bernd Lahrmann
- Niels Grabe
- Dirk Jäger
- Niels Halama
View Affiliations

Affiliations: Department of Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, D-69120 Heidelberg, Germany, Tissue Imaging and Analysis Center (TIGA) and National Center for Tumor Diseases, D-69120 Heidelberg, Germany
Published online on: March 5, 2013 https://doi.org/10.3892/or.2013.2324
Pages: 1697-1700
Copyright: © Zoernig et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

ABCG2 is a multidrug cellular transport protein that is associated with resistance to certain treatments in patients, particularly anticancer treatment. The tumor-protective properties of ABCG2 expression are reported to be a feature of a subset of stem cell-like tumor cells. While protection against chemotherapy has been well analyzed, the role of ABCG2 in the treatment with tyrosine kinase inhibitors is only partially understood. Tyrosine kinase inhibitors are currently the main treatment option in irresectable renal cell carcinomas. To investigate possible underlying sequence variations in the ABCG2 gene with relevance to the functional properties of the protein, 36 patient samples were analyzed. Using sequence analysis and single-nucleotide polymorphism databases, sequence variations in the highly conserved domains of the binding pocket of ABCG2 were analyzed. The resulting variations were used for computational protein prediction algorithms to identify conformational alterations. A relevant shift from A to G at position 1376 (resulting in Y→C at 459 aa) was identified and found to be present in 8.3% of the patients. These patients are currently in follow-up after resection, thus, further analysis will reveal whether this mutation has relevance to treatment efficacy.

View Figures

View References

1	Sagara N and Katoh M: Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation. Cancer Res. 60:5959–5962. 2000.PubMed/NCBI
2	Haimeur A, Conseil G, Deeley RG and Cole SPC: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. 5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
3	Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V and Dean M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:5337–5339. 1998.PubMed/NCBI
4	Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
5	Miyake K, Mickley L, Litman T, et al: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:8–13. 1999.
6	Ewart GD and Howells AJ: ABC transporters involved in transport of eye pigment precursors in Drosophilamelanogaster. Methods Enzymol. 292:213–224. 1998. View Article : Google Scholar : PubMed/NCBI
7	Brangi M, Litman T, Ciotti M, et al: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946. 1999.PubMed/NCBI
8	Litman T, Brangi M, Hudson E, et al: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 113:2011–2021. 2000.PubMed/NCBI
9	Maliepaard M, Scheffer GL, Faneyte IF, et al: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458–3464. 2001.PubMed/NCBI
10	Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E and Chen YC: BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol. 60:831–837. 2000. View Article : Google Scholar : PubMed/NCBI
11	Kawabata S, Oka M, Shiozawa K, et al: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun. 280:1216–1223. 2001. View Article : Google Scholar : PubMed/NCBI
12	Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL and Fojo AT: Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 265:10073–10080. 1990.
13	Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD and Schneider E: Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 60:3514–3521. 2000.
14	Volk EL, Farley KM, Wu Y, Li F, Robey RW and Schneider E: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62:5035–5040. 2002.PubMed/NCBI
15	Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL and Assaraf YG: Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem. 279:25527–25534. 2004. View Article : Google Scholar : PubMed/NCBI
16	Shafran A, Ifergan I, Bram E, et al: ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res. 65:8414–8422. 2005. View Article : Google Scholar : PubMed/NCBI
17	Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E and Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64:2333–2337. 2004. View Article : Google Scholar : PubMed/NCBI
18	Li J, Cusatis G, Brahmer J, et al: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther. 6:432–438. 2007. View Article : Google Scholar : PubMed/NCBI
19	Brendel C, Scharenberg C, Dohse M, et al: Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia. 21:1267–1275. 2007. View Article : Google Scholar : PubMed/NCBI
20	Li Y, Polgar O, Okada M, Esser L, Bates SE and Xia D: Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study. J Mol Graph Model. 25:837–851. 2007. View Article : Google Scholar : PubMed/NCBI
21	Fairbrother WG, Yeo GW, Yeh R, Goldstein P, Mawson M, Sharp PA and Burge CB: RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Res. 32:W187–W190. 2004. View Article : Google Scholar : PubMed/NCBI
22	Fairbrother WG, Holste D, Burge CB and Sharp PA: Single nucleotide polymorphism-based validation of exonic splicing enhancers. PLoS Biol. 2:E2682004. View Article : Google Scholar : PubMed/NCBI
23	Cuff JA, Clamp ME, Siddiqui AS, Finlay M and Barton GJ: JPred: a consensus secondary structure prediction server. Bioinformatics. 14:892–893. 1998. View Article : Google Scholar : PubMed/NCBI
24	Finn RD, Mistry J, Schuster-Bockler B, et al: Pfam: clans, web tools and services. Nucleic Acids Res. 34:D247–D251. 2006. View Article : Google Scholar : PubMed/NCBI
25	Letunic I, Copley RR, Pils B, Pinkert S, Schultz J and Bork P: SMART 5: domains in the context of genomes and networks. Nucleic Acids Res. 34:D257–D260. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lambert C, Leonard N, De Bolle X and Depiereux E: ESyPred3D: prediction of proteins 3D structures. Bioinformatics. 18:1250–1256. 2002. View Article : Google Scholar : PubMed/NCBI
27	To KKW, Zhan Z and Bates SE: Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol. 26:8572–8585. 2006. View Article : Google Scholar : PubMed/NCBI
28	Korenaga Y, Naito K, Okayama N, et al: Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int J Cancer. 117:431–434. 2005. View Article : Google Scholar : PubMed/NCBI
29	Honjo Y, Hrycyna CA, Yan QW, et al: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61:6635–6639. 2001.PubMed/NCBI
30	Ejendal KFK, Diop NK, Schweiger LC and Hrycyna CA: The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 15:1597–1607. 2006. View Article : Google Scholar : PubMed/NCBI